Why the study?
When andexanet alfa is unavailable, factor concentrates are widely used, but data on the reversal effect and lowest effective dose of aPCC to minimize thrombogenicity are limited.
Does activated prothrombin complex concentrate (aPCC) at low concentrations reverse the effect of apixaban and rivaroxaban in vitro?
Does activated prothrombin complex concentrate (aPCC) at low concentrations reverse the effect of apixaban and rivaroxaban in vitro?
In vitro, aPCC concentrations lower than previously reported (0.08-0.24 U/mL) effectively reversed the effects of FXa inhibitors, which may help minimize thrombogenic risk.
Answers are grounded in this paper and cite their sources.
Low-dose aPCC reversal of FXa inhibitors remains hypothesis-generating in vitro; leaves open translation to safe human use.
Factor (F) Xa inhibitors are safe and effective alternatives to warfarin. There are concerns about the lack of a reversal strategy in case of serious bleeds or need for emergency surgery in situations when the antidote andexanet alfa is not available. Factor concentrates are widely used, but there are few clinical studies regarding the reversal effect of activated prothrombin complex concentrate (aPCC). Because of the feared thrombogenicity, administration of the lowest effective dose would be desirable. To determine the lowest concentration of aPCC sufficient to reverse the effect of rivaroxaban and apixaban. Blood from 18 healthy volunteers were supplemented with apixaban or rivaroxaban. aPCC was added to obtain 10 different concentrations ranging from 0.08-1.60 U/mL. Thromboelastometry and thrombin generation assay were used to assess the reversal effect. aPCC concentrations of 0.08 and 0.16 U/mL restored thromboelastometry clotting time to baseline in apixaban ( P = 1.0) and rivaroxaban ( P = 1.0)-containing samples, respectively. The concentrations 0.08 U/mL ( P = 0.5) and 0.24 U/mL ( P = 0.2) were sufficient to restore thrombin generation. Concentrations of 0.56 U/mL and higher, caused significantly higher ETP than baseline in apixaban-containing samples ( P < 0.05). aPCC concentrations lower than previously reported were effective in reversing the effect of FXa inhibitors in vitro.
No takes yet. Share an insight, caveat, or question.
Schultz et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: